Solid Tumor Testing Market Analysis, Size, Share, Growth, Trends, and Forecast
Market Size and Forecast
The global Solid Tumor Testing Market size was valued at USD 23.65 Billion in 2021 and is projected to reach from USD XX Billion in 2022 to USD 40.64 Billion in 2030, growing at a CAGR of 6.2% during the forecast period (2022–2030).
Request a free request sample https://straitsresearch.com/report/solid-tumor-testing-market/request-sample
Market Dynamics and Expansion
The solid tumor testing market is experiencing significant growth due to the increasing prevalence of cancer worldwide. The rising demand for personalized medicine and targeted therapies is driving the adoption of solid tumor testing. Moreover, advancements in technology, such as next-generation sequencing (NGS), are enabling the development of more accurate and efficient testing methods.
Market Segmentation
The solid tumor testing market is segmented into three main categories:
By Type
- Genetic testing: This segment is expected to dominate the market due to the increasing adoption of genetic testing for cancer diagnosis and treatment.
- Conventional testing: This segment is expected to grow at a steady rate due to the continued use of conventional testing methods in cancer diagnosis.
By Cancer Type
- Breast Cancer: This segment is expected to dominate the market due to the high prevalence of breast cancer worldwide.
- Lung Cancer: This segment is expected to grow at a significant rate due to the increasing prevalence of lung cancer.
- Colorectal Cancer: This segment is expected to grow at a steady rate due to the increasing adoption of screening tests for colorectal cancer.
- Prostate Cancer: This segment is expected to grow at a significant rate due to the increasing prevalence of prostate cancer.
- Cervical Cancer: This segment is expected to grow at a steady rate due to the increasing adoption of screening tests for cervical cancer.
By End-User
- Hospitals: This segment is expected to dominate the market due to the high adoption of solid tumor testing in hospitals.
- Pharmaceutical and biotechnology companies: This segment is expected to grow at a significant rate due to the increasing adoption of solid tumor testing in pharmaceutical and biotechnology companies.
- Contract research organizations: This segment is expected to grow at a steady rate due to the increasing adoption of solid tumor testing in contract research organizations.
- Academic research institutions: This segment is expected to grow at a steady rate due to the increasing adoption of solid tumor testing in academic research institutions.
Key Players
The solid tumor testing market is highly competitive, with several key players operating in the market. Some of the top-performing companies in the market include:
- Abbott Laboratories
- Agilent Technologies
- 20/20 Gene Systems Inc.
- Thermo Fisher Scientific, Inc.
- Avant Diagnostics, Inc.
- Advanced Cell Diagnostics, Inc.
- Agena Bioscience, Inc.
- Bio-Rad Laboratories, Inc.
- Johnson & Johnson
- Biocare Medical, LLC.
This Report is available for purchase on @ https://straitsresearch.com/buy-now/solid-tumor-testing-market
Emerging Prospects
The solid tumor testing market is expected to witness significant growth in the coming years due to the increasing adoption of personalized medicine and targeted therapies. The market is also expected to benefit from the increasing use of artificial intelligence (AI) and machine learning (ML) in cancer diagnosis and treatment.
Industry Movements
The solid tumor testing market is witnessing significant industry movements, including partnerships, collaborations, and acquisitions. For example, in 2022, Abbott Laboratories acquired Alere, Inc., a leading provider of point-of-care diagnostic tests.
Geographic Analysis
The solid tumor testing market is segmented into several regions, including North America, Europe, Asia-Pacific, and Rest of the World. North America is expected to dominate the market due to the high prevalence of cancer in the region.
Data Insights
The solid tumor testing market is expected to witness significant growth in the coming years due to the increasing adoption of personalized medicine and targeted therapies. The market is also expected to benefit from the increasing use of AI and ML in cancer diagnosis and treatment.
Key Takeaways:
- The global solid tumor testing market size was valued at USD 23.65 Billion in 2021.
- The market is projected to reach USD 40.64 Billion in 2030, growing at a CAGR of 6.2% during the forecast period.
- The market is segmented into genetic testing and conventional testing, with genetic testing expected to dominate the market.
- The market is also segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, and cervical cancer, with breast cancer expected to dominate the market.
Contact Us:
Email: sales@straitsresearch.com
Address: 825 3rd Avenue, New York, NY, USA, 10022
Tel: +1 646 905 0080 (U.S.)
